GW Pharmaceuticals PLC (NASDAQ:GWPH) was downgraded by stock analysts at Maxim Group from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.

A number of other equities research analysts also recently commented on GWPH. Zacks Investment Research downgraded shares of GW Pharmaceuticals PLC from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. BidaskClub raised shares of GW Pharmaceuticals PLC from a “strong sell” rating to a “sell” rating in a research report on Wednesday, June 14th. TheStreet downgraded shares of GW Pharmaceuticals PLC from a “c-” rating to a “d+” rating in a research report on Wednesday, May 10th. ValuEngine raised shares of GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $208.00 target price on shares of GW Pharmaceuticals PLC in a research report on Tuesday, May 9th. Five analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $156.38.

GW Pharmaceuticals PLC (GWPH) opened at 115.10 on Tuesday. GW Pharmaceuticals PLC has a 1-year low of $79.62 and a 1-year high of $137.88. The stock’s market cap is $2.91 billion. The company has a 50-day moving average price of $105.72 and a 200 day moving average price of $113.95.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last posted its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing analysts’ consensus estimates of ($1.50) by $0.20. GW Pharmaceuticals PLC had a negative return on equity of 22.81% and a negative net margin of 1,021.38%. The company had revenue of $2.04 million during the quarter, compared to the consensus estimate of $2.07 million. During the same period last year, the firm posted ($0.06) EPS. The company’s revenue for the quarter was down 23.0% on a year-over-year basis. Equities analysts expect that GW Pharmaceuticals PLC will post ($5.10) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.dailypolitical.com/2017/08/08/gw-pharmaceuticals-plc-gwph-downgraded-by-maxim-group.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Alliancebernstein L.P. boosted its position in GW Pharmaceuticals PLC by 4.6% in the first quarter. Alliancebernstein L.P. now owns 286,475 shares of the biopharmaceutical company’s stock worth $34,646,000 after buying an additional 12,519 shares during the period. Blair William & Co. IL purchased a new position in GW Pharmaceuticals PLC during the first quarter worth $207,000. Victory Capital Management Inc. boosted its position in GW Pharmaceuticals PLC by 10.4% in the first quarter. Victory Capital Management Inc. now owns 283,025 shares of the biopharmaceutical company’s stock worth $34,229,000 after buying an additional 26,638 shares during the period. Pictet Asset Management Ltd. boosted its position in GW Pharmaceuticals PLC by 81.1% in the first quarter. Pictet Asset Management Ltd. now owns 128,571 shares of the biopharmaceutical company’s stock worth $15,549,000 after buying an additional 57,578 shares during the period. Finally, Creative Planning boosted its position in GW Pharmaceuticals PLC by 179.3% in the first quarter. Creative Planning now owns 2,497 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 1,603 shares during the period. Institutional investors own 75.77% of the company’s stock.

About GW Pharmaceuticals PLC

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Analyst Recommendations for GW Pharmaceuticals PLC (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.